Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

13.61 -0.30 (-2.16%)
Streaming Delayed Price Updated: 11:44 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Recap: Enanta Pharmaceuticals Q3 Earnings ↗
  Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Analyst Ratings for Enanta Pharmaceuticals ↗
Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings: 
Via Benzinga
News headline image
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Expert Ratings for Enanta Pharmaceuticals ↗
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals ↗
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Recap Of Friday's Biotech Catalysts - End of The Day Summary ↗
 
Via Benzinga
News headline image
Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study ↗
Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple... 
Via Benzinga
News headline image
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants ↗
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects.  EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a... 
Via Benzinga
News headline image
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
News headline image
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid ↗
Another company says it invented the technology behind the pill first. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate in Two Investor Conferences in June
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint ↗
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial... 
Via Benzinga
News headline image
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.